Developing new antifungal peptides to fight resistant infections
Optimization and Characterization of Novel Antifungal Peptides
This study is working on developing new treatments to help fight tough fungal infections, like invasive candidiasis, especially for patients who have infections that don't respond to current medicines.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aimmax Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10620239 on NIH RePORTER |
What this research studies
This research focuses on creating and optimizing a new class of antifungal peptides to combat invasive candidiasis, a serious infection caused by fungi. The approach involves designing peptides that can effectively target and kill various Candida species, including those resistant to existing treatments. The research utilizes both in vitro and in vivo testing to evaluate the effectiveness and safety of these peptides, aiming to provide a novel therapeutic option for patients suffering from resistant fungal infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from invasive candidiasis or those at high risk for fungal infections, particularly those with resistant strains.
Not a fit: Patients with fungal infections that are not caused by Candida species may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antifungal treatments that are effective against drug-resistant fungal infections, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in developing antimicrobial peptides, indicating potential for success in this novel approach.
Where this research is happening
Durham, United States
- Aimmax Therapeutics, INC. — Durham, United States (Active)
Researchers
- Principal investigator: Keedy, Kara S — Aimmax Therapeutics, INC.
- Study coordinator: Keedy, Kara S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.